West Pharmaceutical Services, Inc. (WST)

FairStock Score: 46/100 — MIXED

Key Financials

Strengths

• Durable competitive moat in injectable delivery systems with high customer switching costs
• Exceptional net margin of 16.41% demonstrating pricing power and operational efficiency
• Strong financial position: low leverage (D/E 0.10), solid ROE of 16.86%, and healthy FCF generation
• Positioned in secular growth market with biologics and injectable drug adoption trends
• Defensive business model with stable, recurring revenue from pharmaceutical manufacturers

Concerns

• Valuation is egregiously expensive at 449% above Graham intrinsic value with EV/EBITDA of 78.59x
• Declining financial quality signals (Piotroski F-Score of 5/9) warrant investigation
• Anemic FCF yield of 1.0% and low ROCE of 10.09% fail to justify premium multiples
• Stock near 52-week highs ($322.34) with significant downside risk if growth disappoints

AI Analysis

West Pharmaceutical Services operates in an attractive niche—injectable drug delivery systems—with genuine competitive advantages. Their proprietary products command premium margins (16.41% net margin in Q4), reflecting pricing power and customer switching costs. The business benefits from secular tailwinds: rising injectable drug usage, biologics adoption, and pandemic-accelerated demand for prefilled syringes and safety-engineered devices. However, I must be candid about the valuation. At $233.83, we're paying 34.96x earnings with an EV/EBITDA of 78.59x. That's not a discount to quality; it's a premium that assumes perfection. The Graham Number of $42.60 suggests the stock is trading at 449% above intrinsic value—a massive red flag. While the business itself deserves respect—ROE of 16.86%, fortress balance sheet with 0.10 D/E ratio, solid free cash flow of $273.9M—the price leaves no margin of safety. The Piotroski F-Score of 5/9 indicates deteriorating financial quality, and the FairStock Score of 45/100 confirms my concerns. I prefer to buy wonderful businesses at good prices, not mediocre prices for wonderful businesses. At current levels, this is a pass for value investors.

Bull Case

West operates a mission-critical business in healthcare with structural demand growth from biologics and prefilled syringe adoption. If management executes on operational leverage and international expansion, 15%+ annual earnings growth could justify elevated multiples, particularly amid industry consolidation. Strong free cash flow supports dividends and buybacks for shareholder returns.

Bear Case

At 78.59x EV/EBITDA, any slowdown in pharmaceutical industry capex spending or margin compression would trigger severe repricing. The Piotroski deterioration and minimal margin of safety mean valuation reversion is a material risk, with the stock capable of correcting 40-50% if growth inflects downward.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer